JP2022529823A - ドライアイの治療に使用可能な組成物および方法 - Google Patents

ドライアイの治療に使用可能な組成物および方法 Download PDF

Info

Publication number
JP2022529823A
JP2022529823A JP2021562906A JP2021562906A JP2022529823A JP 2022529823 A JP2022529823 A JP 2022529823A JP 2021562906 A JP2021562906 A JP 2021562906A JP 2021562906 A JP2021562906 A JP 2021562906A JP 2022529823 A JP2022529823 A JP 2022529823A
Authority
JP
Japan
Prior art keywords
sodium
pharmaceutical composition
chloride
listeganib
taurine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021562906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529823A5 (https=
Inventor
エル． カラジョージアン、ハンパー
ワイ． パーク、ジョン
エイチ． カラジョージアン、ビッケン
アルビス サライーバ、メルビン
エス． カラジョージアン、リサ
エム． オーベル、ジャニーヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allegro Ophthalmics LLC
Original Assignee
Allegro Ophthalmics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allegro Ophthalmics LLC filed Critical Allegro Ophthalmics LLC
Publication of JP2022529823A publication Critical patent/JP2022529823A/ja
Publication of JP2022529823A5 publication Critical patent/JP2022529823A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021562906A 2019-04-22 2020-04-21 ドライアイの治療に使用可能な組成物および方法 Pending JP2022529823A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962836858P 2019-04-22 2019-04-22
US62/836,858 2019-04-22
PCT/US2020/029168 WO2020219475A1 (en) 2019-04-22 2020-04-21 Compositions and methods useable for treatment of dry eye

Publications (2)

Publication Number Publication Date
JP2022529823A true JP2022529823A (ja) 2022-06-24
JP2022529823A5 JP2022529823A5 (https=) 2023-05-10

Family

ID=72941233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562906A Pending JP2022529823A (ja) 2019-04-22 2020-04-21 ドライアイの治療に使用可能な組成物および方法

Country Status (9)

Country Link
US (1) US20200345805A1 (https=)
EP (1) EP3958915A4 (https=)
JP (1) JP2022529823A (https=)
KR (1) KR20220003548A (https=)
CN (1) CN114040783A (https=)
CA (1) CA3134362A1 (https=)
IL (1) IL287441A (https=)
MX (1) MX2021012857A (https=)
WO (1) WO2020219475A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346362B (es) * 2009-11-10 2017-03-15 Allegro Pharmaceuticals Inc * Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd.
US12454549B2 (en) 2017-06-19 2025-10-28 Jenius Pharma, Llc Treatments for diseases and disorders that involve oxidative stress

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10218790A (ja) * 1997-02-10 1998-08-18 Kazuo Tsubota 分泌腺細胞とリンパ球との接着阻害剤
JP2000336030A (ja) * 1999-03-24 2000-12-05 Taisho Pharmaceut Co Ltd 点眼液
JP2008545656A (ja) * 2005-05-17 2008-12-18 サーコード コーポレイション 眼障害の治療のための組成物および方法
JP2013510863A (ja) * 2009-11-10 2013-03-28 アレグロ ファーマシューティカルズ インコーポレイテッド 細胞接着を阻害するため、またはｒｇｄ結合部位に診断用薬もしくは治療薬を送達するための組成物および方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104798A1 (en) * 1999-10-04 2007-05-10 S.K. Pharmaceuticals, Inc. Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide
JP4255656B2 (ja) * 2001-09-17 2009-04-15 株式会社メニコン 眼科用液剤及びコンタクトレンズ用液剤
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US10842669B2 (en) * 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
ITRM20090102U1 (it) * 2009-06-15 2010-12-16 Alfa Intes Ind Terapeutica Splendore S R L Ialuvit preparato per la stabilizzazione del film lacrimale, la cicatrizzazione corneale e il ripristino del contenuto salino della lacrima e osmoprotezione.
WO2011106697A1 (en) * 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
CA2849192C (en) * 2011-10-12 2019-09-24 Ascendis Pharma Ophthalmology Division A/S Prevention and treatment of ocular conditions
TWI700085B (zh) * 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
US11433260B2 (en) * 2015-12-21 2022-09-06 Gholam A. Peyman Cancer treatment methods using thermotherapy and/or enhanced immunotherapy
PT3266446T (pt) * 2016-07-07 2019-01-30 Salvat Lab Sa Composição oftálmica compreendendo óleo de rícino e triglicérido de cadeia média
EP4389216A3 (en) * 2017-06-19 2024-11-06 Allegro Pharmaceuticals, LLC Peptide compositions and therapeutic uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10218790A (ja) * 1997-02-10 1998-08-18 Kazuo Tsubota 分泌腺細胞とリンパ球との接着阻害剤
JP2000336030A (ja) * 1999-03-24 2000-12-05 Taisho Pharmaceut Co Ltd 点眼液
JP2008545656A (ja) * 2005-05-17 2008-12-18 サーコード コーポレイション 眼障害の治療のための組成物および方法
JP2013510863A (ja) * 2009-11-10 2013-03-28 アレグロ ファーマシューティカルズ インコーポレイテッド 細胞接着を阻害するため、またはｒｇｄ結合部位に診断用薬もしくは治療薬を送達するための組成物および方法

Also Published As

Publication number Publication date
EP3958915A4 (en) 2023-01-11
IL287441A (en) 2021-12-01
MX2021012857A (es) 2021-12-10
CA3134362A1 (en) 2020-10-29
CN114040783A (zh) 2022-02-11
EP3958915A1 (en) 2022-03-02
US20200345805A1 (en) 2020-11-05
WO2020219475A1 (en) 2020-10-29
KR20220003548A (ko) 2022-01-10

Similar Documents

Publication Publication Date Title
JP7432654B2 (ja) 人工涙液、コンタクトレンズ及び薬剤担体組成物並びにその使用方法
Marcano et al. Synergistic cysteamine delivery nanowafer as an efficacious treatment modality for corneal cystinosis
Li et al. Glaucoma and ocular surface disease: more than meets the eye
JP2003523925A (ja) 乾燥性眼病の局所治療のためのテトラサイクリンを含む眼科用溶液
CN102639136A (zh) 前列腺素F2α及类似物用于愈合角膜和结膜损害的用途
Rusciano et al. Free amino acids: an innovative treatment for ocular surface disease
JP2020510037A (ja) ドライアイ疾患のためのペプチド
Cheema et al. Sodium hyaluronate eye drops in the treatment of dry eye disease: an open label, uncontrolled, multi-centre trial
US20140322193A1 (en) Therapies for Disorders of the Cornea and Conjunctiva
US20230338307A1 (en) Prophylactic agent, ameliorating agent, and therapeutic agent for dry eye
JP2022529823A (ja) ドライアイの治療に使用可能な組成物および方法
US20210213103A1 (en) Methods of treating dry eye syndrome
CN112292135A (zh) 用于治疗和预防严重眼表疾病的高分子量透明质酸
AU2639799A (en) Remedies for corneal epithelium disturbance
JP7742649B2 (ja) ドライアイ疾患のためのｔｓｇ６ポリペプチドフラグメント
JP7404658B2 (ja) 涙液層安定化剤及びマイバム分泌促進剤
El Fekih et al. Successful management of dry eye disease with a new eye drop formulation combining hyaluronic acid, trehalose, and N-acetyl-aspartyl-glutamic acid (NAAGA)
RU2652581C1 (ru) Способ лечения роговично-конъюнктивального ксероза
HK40070050A (en) Compositions and methods useable for treatment of dry eye
JP2016029030A (ja) 角結膜障害治療剤
Velpandian et al. Mucoadhesive polymers and ocular lubricants
Kasetsuwan et al. A sodium hyaluronate ophthalmic solution for reducing dry eye and enhancing corneal wound healing after photorefractive keratectomy (PRK)
Gowtham et al. 6 Newer Drugs in Glaucoma
solution Suspension Materials and methods Study design
Al-Mugheiry et al. Once-daily Preservative-free Topical Anti-glaucomatous Monotherapy–A Better Approach?

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241022